InvestorsHub Logo
Followers 5
Posts 2466
Boards Moderated 0
Alias Born 08/16/2016

Re: None

Wednesday, 08/03/2022 10:52:27 AM

Wednesday, August 03, 2022 10:52:27 AM

Post# of 3186
State of New Jersey Common Pension Fund D trimmed its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) by 34.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 96,642 shares of the biopharmaceutical company’s stock after selling 50,023 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in ACADIA Pharmaceuticals were worth $2,341,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the stock. Lazard Asset Management LLC grew its position in shares of ACADIA Pharmaceuticals by 19.4% in the 4th quarter. Lazard Asset Management LLC now owns 3,115 shares of the biopharmaceutical company’s stock valued at $72,000 after buying an additional 506 shares during the last quarter. Personal CFO Solutions LLC grew its position in shares of ACADIA Pharmaceuticals by 6.7% in the 1st quarter. Personal CFO Solutions LLC now owns 15,846 shares of the biopharmaceutical company’s stock valued at $384,000 after buying an additional 1,000 shares during the last quarter. Kalos Management Inc. grew its position in shares of ACADIA Pharmaceuticals by 6.0% in the 4th quarter. Kalos Management Inc. now owns 19,689 shares of the biopharmaceutical company’s stock valued at $340,000 after buying an additional 1,114 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of ACADIA Pharmaceuticals by 8.0% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,927 shares of the biopharmaceutical company’s stock valued at $434,000 after buying an additional 1,334 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale grew its position in shares of ACADIA Pharmaceuticals by 2.7% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 68,700 shares of the biopharmaceutical company’s stock valued at $1,637,000 after buying an additional 1,800 shares during the last quarter. 91.74% of the stock is owned by hedge funds and other institutional investors.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ACAD News